三年在线观看免费观看,日本成本人片不卡无码免费,成品人和精品人的区别三叶草,欧美国产日韩a在线视频y

Your location:Home > Newsroom > Industry News

Cancer Biomarker Market to Grow to $7.4B in 2020


 

Advances in technology will propel the cancer biomarker market to grow as more people use them to test, screen and determine risk for cancer. 

 

A new report shows that the cancer biomarker testing market will grow to $7.4 billion in 2020, up from $4.8 million last year.

 

According to Kalorama, a market research company that published the report, these types of tests have shown faster revenue growth than in vitro diagnostics overall. But the technologies are not simply to simply screen for cancer, test for cancer or determine the risk of cancer, the latter having been made famous by Angelina Jolie testing for the BRCA1 biomarker of breast cancer.

 

These tests are also to aid in prognosis and personalize therapy. For instance, companies like Foundation Medicine and Caris Lifesciences offer tests that can help oncologists determine if there are certain therapies that cancer patients will respond to better than others. 

 

"Once a cancer is diagnosed, physicians often need additional information about the genetic changes and characteristics of a cancer to aid in the decision about what therapy to select to treat the patient," said Bruce Carlson, Publisher of Kalorama Information, in a news release. "These genetic changes may result in over-expression of certain proteins, or in the absence of certain protein activities. A growing number of options and tests are becoming available for this."

 

Worldwide, cancer is the number two cause of death, behind only cardiovascular disease. The International Agency for Cancer, World Health Organization, reports that the estimated incidence of cancer worldwide in 2012 was 14,068,000, according to the report.

 

Globally, the most common types of cancer are breast cancer, colorectal cancer, lung cancer, and prostate cancer and these are also common cancers in the United States and Europe. As such, they are the focus of much therapeutic and diagnostic activities, and the focus of much of the cancer biomarker activity, according to the report.

About AVE   |   Newsroom   |   Products   |   Service   |   Contact Us
◎China. Changsha. AVE Science & Technology Co.Ltd. All Rights Reserved
<label id="pmmrb"></label>

<ul id="pmmrb"></ul>

    主站蜘蛛池模板: 宣威市| 西充县| 肥城市| 宣恩县| 成都市| 灵石县| 荥经县| 南阳市| 德州市| 本溪市| 布尔津县| 长海县| 德州市| 清河县| 三穗县| 颍上县| 日土县| 怀集县| 阿巴嘎旗| 大港区| 富阳市| 常山县| 江西省| 大兴区| 陆河县| 大石桥市| 丹凤县| 镇雄县| 浦县| 闸北区| 天津市| 永城市| 拜城县| 仙桃市| 保德县| 苍南县| 松江区| 林芝县| 龙海市| 腾冲县| 西乌珠穆沁旗|